2seventy bio is being acquired by Bristol Myers Squibb in an all-cash deal at $5 per share, with the merger set to close in Q2 2025. Despite Abecma generating $242 million in U.S. sales, 2seventy ...

A Bristol Myers Squibb Co. patent detailed new substituted phenyl oxooxazolyl piperidine dione molecular glue degraders acting as DNA-binding protein Ikaros (IKZF1), zinc finger protein Helios (IKZF2) ...

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology ...

Bristol Myers Squibb BMY announced that it has obtained FDA approval for the label expansion of Opdivo (nivolumab) plus ...

Bristol Myers Squibb has moved to take full control of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286m.

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies. For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...